We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KVUE:NYSEKenvue Inc. Analysis

Data as of 2026-07-22 - not real-time

$19.19

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

KVUE is trading at $19.19, marginally above its 20‑day SMA (19.17) and comfortably above the 50‑day (18.22) and 200‑day (17.41) averages, confirming a short‑term bullish bias. The RSI sits at 56.7, indicating neutral momentum, while the MACD histogram is negative and the signal line is bearish, suggesting that upward momentum may be waning. Volume has been decreasing, and the 30‑day volatility of 22.5% is relatively high for a consumer‑defensive name, though the stock’s beta of 0.13 points to minimal market‑wide risk. The dividend yield of 4.37% is attractive, but the payout ratio of 98.5% raises sustainability concerns.
Fundamentally, KVUE posted 4.5% revenue growth, solid gross (58.6%) and operating (21.6%) margins, and a 15.7% ROE, yet carries a high net‑debt load (debt‑to‑equity 83) and a DCF‑derived fair value of $11.19, implying the market is pricing significant acquisition‑related premium. The announced $48.7 billion Kimberly‑Clark takeover has lifted the stock 14.5% over the past month, but analysts remain mixed, with a consensus “hold” and a modest 2.95% upside versus current price. These dynamics suggest that while the stock offers a strong dividend and defensive positioning, upside may be limited until the deal closes and integration risks are resolved.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Acquisition premium already priced in
  • Bearish MACD signal despite price above short‑term averages
  • High dividend payout ratio may limit cash flow

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Potential synergies from Kimberly‑Clark integration
  • Forward PE of 15.5 suggests value relative to earnings growth
  • Moderate debt load could constrain flexibility

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic fit may improve margins and cash flow
  • Defensive consumer‑health exposure supports stability
  • Attractive dividend yield if payout ratio normalizes

Key Metrics & Analysis

Financial Health

Revenue Growth4.50%
Profit Margin10.61%
P/E Ratio22.8
ROE15.70%
ROA7.07%
Debt/Equity82.97
P/B Ratio3.5
Op. Cash Flow$2.3B
Free Cash Flow$1.9B

Technical Analysis

TrendBullish
RSI56.7
Support$18.46
Resistance$20.13
MA 20$19.17
MA 50$18.22
MA 200$17.41
MACDBearish
VolumeDecreasing
Fear & Greed Index91.5

Valuation

Fair Value$11.19
Target Price$19.75
Upside/Downside2.95%
GradeFair
TypeBlend
Dividend Yield4.37%

Risk Assessment

Beta0.13
Volatility22.54%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.